Vatalanib
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
180px | |
Systematic (IUPAC) name | |
---|---|
N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin- 1-amine | |
Clinical data | |
Pregnancy category |
|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High |
Metabolism | Extensive hepatic metabolism (mostly CYP3A4-mediated)[1] |
Biological half-life | 4.6 ± 1.1 h[1] |
Excretion | Fecal and renal[1] |
Identifiers | |
CAS Number | 212141-54-3 |
ATC code | none |
PubChem | CID 151194 |
ChemSpider | 133257 |
Chemical data | |
Formula | C20H15ClN4 |
Molar mass | 346.813 g·mol−1[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.
Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.[1][2][3][4]
Development
Vatalanib was discovered through high-throughput screening.[2] It has been extensively investigated in Phase I, II and III clinical trials.[1][4] Two large, randomized controlled Phase III trials have studied the effect of adding vatalanib to the FOLFOX chemotherapy regimen in people with metastatic colorectal cancer: CONFIRM-1, whose participants had not yet received any treatment for their cancer; and CONFIRM-2, in which participants had received first-line treatment with irinotecan and fluoropyrimidines. Vatalanib produced no significant improvement in overall survival (the primary endpoint of the studies), although it did significantly increase progression-free survival in CONFIRM-2.[4] Both trials found that progression-free survival was improved in people with high levels of lactate dehydrogenase, an enzyme used as a marker of tissue breakdown; the reasons for and implications of this difference are still unclear.[4][5]
Adverse effects
The adverse effects of vatalanib appear similar to those of other VEGF inhibitors. In the CONFIRM trials, the most common side effects were high blood pressure, gastrointestinal upset (diarrhea, nausea, and vomiting), fatigue, and dizziness.[4]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Ongoing and completed clinical trials of vatalanib at ClinicalTrials.gov (U.S. National Institutes of Health)
- ↑ 1.0 1.1 1.2 1.3 1.4 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ 2.0 2.1 Mariani SM (2004). "Antiangiogenesis cocktails—stirred or shaken?". Medscape General Medicine. 6 (4): 21. PMC 1480579 Freely accessible. PMID 15775848. Retrieved on October 29, 2008.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ 4.0 4.1 4.2 4.3 4.4 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Pages with broken file links
- Orphaned articles from February 2009
- Articles with invalid date parameter in template
- All orphaned articles
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Angiogenesis inhibitors
- Tyrosine kinase inhibitors